

Hans Hendriks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7712155/publications.pdf>

Version: 2024-02-01

31
papers

1,101
citations

394390

19
h-index

434170

31
g-index

32
all docs

32
docs citations

32
times ranked

1393
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. <i>Biology of the Cell</i> , 1995, 83, 105-120.	2.0	131
2	EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. <i>European Journal of Cancer</i> , 1993, 29, 897-906.	2.8	112
3	High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. <i>Annals of Oncology</i> , 1999, 10, 1233-1240.	1.2	90
4	Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. <i>Biochemical Pharmacology</i> , 2004, 67, 503-511.	4.4	81
5	Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. <i>Investigational New Drugs</i> , 2011, 29, 456-466.	2.6	76
6	EO9 (Apaziquone): from the clinic to the laboratory and back again. <i>British Journal of Pharmacology</i> , 2013, 168, 11-18.	5.4	67
7	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. <i>Oncotarget</i> , 2017, 8, 48507-48520.	1.8	63
8	Depletion of macrophages and disappearance of postcapillary high endothelial venules in lymph nodes deprived of afferent lymphatic vessels. <i>Cell and Tissue Research</i> , 1980, 211, 375-89.	2.9	57
9	Innovation in oncology clinical trial design. <i>Cancer Treatment Reviews</i> , 2019, 74, 15-20.	7.7	41
10	KML001 Cytotoxic Activity Is Associated with Its Binding to Telomeric Sequences and Telomere Erosion in Prostate Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 4593-4602.	7.0	39
11	Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. <i>General Pharmacology</i> , 1996, 27, 421-429.	0.7	34
12	A study of the delivery-targeting concept applied to antineoplastic drugs active on human osteosarcoma. I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues. <i>European Journal of Medicinal Chemistry</i> , 1992, 27, 825-833.	5.5	32
13	The antitumour activity of the prodrug N-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts. <i>European Journal of Cancer</i> , 1998, 34, 1602-1606.	2.8	30
14	Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Arabinosylcytosine (ara-C) in Leukemia and Solid Tumor Cell Lines. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1523-1526.	1.1	29
15	Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Gemcitabine in Leukemia and Solid Tumor Cell Lines and in Human Xenografts. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1329-1333.	1.1	28
16	Cycloplatin: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. <i>European Journal of Cancer</i> , 1995, 31, 356-361.	2.8	27
17	Superior therapeutic efficacy of N-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. <i>European Journal of Cancer</i> , 1999, 35, 1143-1149.	2.8	23
18	Alkyl and Alkoxyethyl Antineoplastic Phospholipids. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2609-2614.	6.4	21

#	ARTICLE	IF	CITATIONS
19	No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone. <i>Anti-Cancer Drugs</i> , 2000, 11, 659-664.	1.4	21
20	Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 783-791.	3.3	21
21	Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts. <i>European Journal of Cancer</i> , 1992, 28, 767-773.	2.8	18
22	KW-2149 (7-N-[2-[Y-L-glutamylamino]ethylthioethyl]mitomycin C) a new mitomycin c analogue activated by serum. <i>Biochemical Pharmacology</i> , 1997, 53, 279-285.	4.4	14
23	Phagocytosis and lipofuscin accumulaton in lymph node macrophages. <i>Mechanisms of Ageing and Development</i> , 1986, 35, 161-167.	4.6	9
24	The Endothelium of the High Endothelial Venule: A Specialized Endothelium with Unique Properties. <i>Pathobiology</i> , 1987, 55, 1-10.	3.8	8
25	Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. <i>British Journal of Cancer</i> , 2017, 117, 195-202.	6.4	6
26	Mesenteric lymph nodes: cells with surface and sytoplasmic immunoglobulins. <i>Vigiliae Christianae</i> , 1984, 47, 123-129.	0.1	5
27	Flunarizine as a modulator of doxorubicin resistance in human colon-adenocarcinoma cells. <i>International Journal of Cancer</i> , 1993, 55, 636-639.	5.1	5
28	Isolation of high numbers of lymphoid cells from single lymph nodes from the rat. <i>Journal of Immunological Methods</i> , 1976, 12, 345-346.	1.4	3
29	New EORTC compounds. <i>Cancer Treatment Reviews</i> , 1990, 17, 119-125.	7.7	3
30	Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. <i>Npj Precision Oncology</i> , 2021, 5, 96.	5.4	2
31	The role of pharmacology in anticancer drug development. <i>ADMET and DMPK</i> , 2018, 6, 4.	2.1	0